Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

• Status: Recruiting
• Trial end date: 2025-03-14
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase II, open label, prospective, single-arm study evaluating the efficacy and safety of selinexor in patients with PMF or secondary MF (PPV-MF or PET-MF) who are refractory or intolerant to ruxolitinib and/or any other experimental JAK1/2 inhibitors.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Utah
• Collaborator: Karyopharm Therapeutics Inc

Criteria

Inclusion Criteria:

• Male or female subject aged ≥ 18 years.

• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

• Diagnosis of primary myelofibrosis (PMF), post-essential thrombocytosis (PET-MF) or post-polycythemia vera (PPV-MF).

• Life expectancy ≥ 6 months.

• Prior treatment with ruxolitinib or any experimental JAK1/2 inhibitor with any one or more of the following:

a. Inadequate response after being on ≥ 3 months of treatment defined by: i. Palpable spleen ≥ 10 cm below the left subcostal margin on physical examination at the screening visit OR ii. Palpable spleen ≥ 5cm below the left subcostal margin on physical examination at the screening visit AND active symptoms of MF at the screening visit defined presence of 1 symptom score of ≥ 5 or two symptom scores each of ≥ 3 using the Screening Symptoms Form (Appendix 6) b. Intolerant to ruxolitinib and/or other JAK1/2 inhibitors due to any grade ≥ 3 non-hematologic AEs of or any grade ≥ 2 AEs requiring treatment discontinuation AND palpable spleen ≥ 5cm below the left subcostal margin on physical examination at the screening visit.

• Adequate organ function as defined as:

• Hematologic (≤ 7 days prior to C1D1):

• Total white blood cell (WBC) count ≥ 1000/mm3

• Absolute neutrophil count (ANC) ≥ 500/mm3

• Hemoglobin ≥ 7 g/dL

• Platelet count ≥ 30,000/mm3

For patients receiving transfusion and growth factor support, the following delays must be observed between the last administration and hematologic laboratory screening assessments:

• For hematopoietic growth factor support (including erythropoietin, darbepoetin, granulocyte-colony stimulating factor [G-CSF], granulocyte macrophage-colony stimulating factor [GM-CSF], and platelet stimulators [e.g., eltrombopag, romiplostim, or interleukin-11]): at least 2 weeks.

Growth factor support, RBC and/or platelet transfusions are allowed as clinically indicated per institutional guidelines during the study.

• Hepatic (≤ 28 days prior to C1D1):

• Total bilirubin < 1.5 × ULN except in patients with indirect hyperbilirubinemia due to hemolysis or with Gilbert's syndrome where total bilirubin should be < 5 × ULN

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 × ULN.

• Renal (within 28 days prior to C1D1):

• Estimated creatinine clearance (CrCl) ≥ 20 mL/min using the Cockroft and Gault formula [(140-Age) × Mass (kg)/(72 × creatinine mg/dL), multiply by 0.85 if the patient is female] OR

• Female patients of childbearing potential must have a negative serum pregnancy test (≤ 3 days prior to C1D1).

• Female patients of childbearing potential must agree to use 2 methods of contraception throughout the study and for 3 months following the last dose of study treatment (including 1 highly effective and 1 effective method of contraception as defined in section 7.4)

• Male patients must use an effective barrier method of contraception if sexually active with a female of childbearing potential.

• Recovery to baseline or ≤ Grade 1 CTCAE v5.0 from toxicities related to any prior treatments including ruxolitinib or other experimental agents, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.

• Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria:

• Prior exposure to a SINE compound, including selinexor.

• BSA < 1.4 m2 at baseline, calculated by the Dubois or Mosteller methods.

• Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals ≤ 1 week prior to C1D1. Patients on prophylactic antibiotics or with a controlled infection ≤ 1 week prior to C1D1 are acceptable.

• Radiation, chemotherapy, immunotherapy, or any other anticancer therapy (including investigational therapies) ≤ 2 weeks.

• Ruxolitinib or other JAK1/2 inhibitors ≤ at least 3 days or 5 half-lives prior to C1D1.

• Major surgery ≤ 4 weeks prior to C1D1.

• Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus ribonucleic acid (RNA) or hepatitis B virus surface antigen.

• Any active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment.

• Any life-threatening illness, organ system dysfunction, or serious psychiatric, medical, or other conditions/situations which, in the investigator's opinion, could compromise a patient's ability to give informed consent, safety, or compliance with the protocol.

• Contraindication to any of the required concomitant drugs or supportive treatments.

• Subjects taking prohibited medications as described in Section 6.3. Following discontinuation of prohibited medications, a washout period is required prior to initiating study treatment (the duration of the washout must be as clinically indicated, e.g. at least five half-lives).

• Subjects who are breastfeeding and unwilling to stop while on study